Thaci D, Gordon K, Gooderham M, Strober B, Korman N, Banerjee S, Banerjee S, Colston E, Kim J, Throup J, Morita A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. J of Skin [Internet]. 2021Nov.5 [cited 2022Aug.12];5(6):s37. Available from: https://jofskin.org/index.php/skin/article/view/1388